Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis.

Of these, four patients (10%) suffered primary failure by not reaching PASI75 at week 16, and six patients (15%) suffered secondary failure by losing PASI75 at week 16. For patients initiating I de novo i biologic therapy, the inclusion criteria were patients over 18 years of age, with moderate-to-severe psoriasis who had a Psoriasis Area and Severity Index (PASI) and BSA (body surface area) greater than 7, and/or Dermatology Life Quality Index (DLQI) higher than 10. Specifically, 73 patients with stabilized disease started treatment with biosimilar adalimumab after switching from the original adalimumab, and 40 patients started I de novo i biosimilar adalimumab. [Extracted from the article]